<DOC>
	<DOCNO>NCT01777269</DOCNO>
	<brief_summary>This European double-blind , placebo control parallel group comparison DUODART ( fix dose combination dutasteride 0.5mg tamsulosin 0.4mg , one capsule daily ) placebo . PRIMARY OBJECTIVE : To assess change sexual function baseline 1 year sexually active men least moderate BPH treat DUODART , compare men treat placebo .</brief_summary>
	<brief_title>Prospective Sexual Function Study BPH Subjects</brief_title>
	<detailed_description>This European double-blind , placebo control parallel group comparison DUODART ( fix dose combination dutasteride 0.5mg tamsulosin 0.4mg , one capsule daily ) placebo . Men eligible screening randomise , 4 week placebo run-in , 2 treatment group 1:1 ratio . All men receive standardise lifestyle advice ( primarily concern weight management exercise ) relevant maintain sexual function . Men also receive standardise lifestyle advice leaflet BPH . The double blind phase continue 12 month , assessment visit 2 week month 1 , 3 , 6 , 9 final visit month 12 . Subjects sexual adverse event double blind phase continue follow schedule study visit resolution adverse event visit 6 month last dose study medication , whichever sooner . PRIMARY OBJECTIVE : To assess change sexual function baseline 1 year sexually active men least moderate BPH ( international prostate symptom score - IPSS = &gt; 12 ) treat DUODART , compare men treat placebo . Change sexual function assess change total score full men 's sexual health questionnaire ( MSHQ ) domains erectile dysfunction , ejaculatory function libido .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<criteria>Males age ≥50 year . Men must sexually active . A man consider sexually active engage sexual activity partner past 4 week ( least ) plan active next 4 week ( unless due travel practical reason ) . Men confirm stable relationship expect maintain sexual activity next year . A confirm clinical diagnosis BPH . International Prostate Symptom Score ( IPSS ) ≥12 Visit 1 ( screen ) , bother score 4 less ( score IPSS Quality Life question 8 ) . Prostate volume ≥30 cc ( transrectal ultrasonography ; TRUS ) . Measurement available baseline visit make /arranged screen visit within previous 6 month . Total serum prostate specific antigen ( PSA ≥1.5 ng/mL ( see exclusion criterion 1 ) Visit 1 ( screen ) . Willing able give sign write informed consent comply study procedure , include ability participate study full 1 year ( 18 month necessary persistent sexual AE ) . Fluent literate local language ability read , comprehend record information MSHQ , IPSS , PPSM , BPH Impact Index ( BII ) CSSRS questionnaire . Able swallow retain oral medication . Men female partner childbearing potential must either agree use effective contraception prior vasectomy . Contraception must use 2 week prior administration first dose study treatment least 5 halflives drug ( 45 day ) plus 3 month ( i.e . total 4.5 month ) allow clearance alter sperm last dose study treatment . French subject : In France , subject eligible inclusion study either affiliate beneficiary social security category . Total serum PSA &gt; 10.0 ng/mL Visit 1 ( screen ) . History evidence prostate cancer ( e.g . positive biopsy ultrasound , suspicious DRE and/or rise PSA ) . Subjects suspicious ultrasound DRE negative biopsy within precede 6 month stable PSA eligible study . Note : If total serum PSA &gt; 4ng/mL unless PSA value stable least past 2 year , investigator make every appropriate effort exclude possibility prostate cancer , include consideration prostate biopsy . Excluded medication therapy Current prior use ( within period give ) follow prohibited medication Any prior use 5αreductase inhibitor ( finasteride dutasteride ) , Anticholinergics ( e.g . oxybutynin , propantheline , tolerodine , solifenacin darifenacin ) within 1 month prior visit 2 ( baseline ) An alphaadrenoreceptor blocker ( i.e . indoramin , prazosin , terazosin , tamsulosin , alfuzosin doxazosin ) within 1 month prior visit 2 ( baseline ) Use drug antiandrogenic property ( e.g . spironolactone , flutamide , bicalutamide , cimetidine , ketoconazole , progestational agent ) within 6 month prior visit 1 ( screen ) . Use drug note propensity cause gynaecomastia , could affect prostate volume , within 6 month prior Visit 1 ( screen ) . Use investigational market study drug within 30 day 5 halflives drug question , ( whichever longer ) , precede visit 2 ( baseline ) . Current use ( baseline visit within prior 1month ) : PDE5 inhibitor Erectile Dysfunction . Anabolic steroid . Drugs known think interaction tamsulosin , e.g . cimetidine warfarin . Use phytotherapy BPH within 2 week prior Visit 1 ( screen ) and/or predict need phytotherapy study . History know ( immediate delay ) hypersensitivity reaction idiosyncratic reaction drug chemically relate study medication excipients , opinion Investigator GSK , contraindicate participation . Previous prostatic surgery ( include TURP , balloon dilatation , thermotherapy stent replacement ) invasive minimally invasive procedure treat BPH . Recent Medical Procedures History flexible/rigid cystoscopy instrumentation urethra within 7 day prior Visit 1 ( screen ) . Catheterisation ( &lt; 10F ) acceptable time restriction . Medical history Presence structural abnormality Lower Urinary Tract sexual organ ( e.g . urethral stricture , Peyronie 's Disease etc ) may cause LUTS sexual dysfunction . History AUR . Postvoid residual volume &gt; 100 mL ( suprapubic ultrasound ) Visit 1 ( screen ) record PVR level previous examination . Measurement available baseline visit make /arranged screen visit within previous 6 month . Any cause BPH , may judgement investigator , result urinary symptom ( e.g . neurogenic bladder , bladder neck contracture , urethral stricture , bladder malignancy , acute chronic prostatitis , acute chronic urinary tract infection ) . History 'first dose ' hypotensive episode initiation alpha1adrenoreceptor antagonist therapy . History postural hypotension , dizziness , vertigo sign symptom orthostasis , opinion investigator could exacerbate tamsulosin result put subject risk injury . History breast cancer clinical breast examination find unclear origin suggestive malignancy . Prior history malignancy ( basal cell carcinoma squamous cell carcinoma skin ) within past 5 year . Subjects earlier history malignancy evidence disease least past 5 year eligible . History hepatic impairment abnormal liver function test Visit 1 ( screen ) ( define ALT , AST alkaline phosphatase &gt; 2 time ULN , total bilirubin &gt; 1.5 time ULN ( unless associate predominantly indirect bilirubin elevation Gilbert 's syndrome ) . History renal insufficiency , serum creatinine &gt; 1.5 time upper limit normal Visit 1 ( screen ) . Any unstable , serious coexist medical condition ( ) include , limited , myocardial infarction , coronary bypass surgery , unstable angina , cardiac arrhythmia , clinically evident congestive heart failure , cerebrovascular accident within 6 month prior Screening visit ; uncontrolled diabetes peptic ulcer disease uncontrolled medical management . History current evidence drug alcohol abuse within previous 12 month . History presence serious and/or unstable preexist psychiatric disorder condition opinion Investigator GSK Medical Monitor , could interfere subject 's safety , obtain informed consent , compliance study procedure , confound result study .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>